{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=25",
    "query": {
      "intervention": "Control II",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 2665,
    "total_pages": 267,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+II&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T22:48:54.770Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001934",
      "title": "Zenapax to Treat Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Zenapax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "1999-09",
      "completion_date": "2008-09",
      "has_results": false,
      "last_update_posted_date": "2011-08-05",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001934"
    },
    {
      "nct_id": "NCT01936363",
      "title": "Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Pimasertib once daily",
          "type": "DRUG"
        },
        {
          "name": "Pimasertib placebo",
          "type": "DRUG"
        },
        {
          "name": "SAR245409 placebo",
          "type": "DRUG"
        },
        {
          "name": "SAR245409",
          "type": "DRUG"
        },
        {
          "name": "Pimasertib twice daily",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 65,
      "start_date": "2013-09-30",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2018-12-12",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 17,
      "location_summary": "Augusta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 13 more",
      "locations": [
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Silver Spring",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01936363"
    },
    {
      "nct_id": "NCT06561087",
      "title": "Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Premalignant Lesion"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-02-27",
      "completion_date": "2029-05-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06561087"
    },
    {
      "nct_id": "NCT03796884",
      "title": "Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Adenoma",
        "Stage 0 Colorectal Cancer AJCC v8",
        "Stage I Colorectal Cancer AJCC v8",
        "Stage II Colorectal Cancer AJCC v8",
        "Stage IIA Colorectal Cancer AJCC v8",
        "Stage IIB Colorectal Cancer AJCC v8",
        "Stage IIC Colorectal Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Linaclotide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2019-10-30",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • Seattle, Washington",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796884"
    },
    {
      "nct_id": "NCT05645692",
      "title": "A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Tobemstomig",
          "type": "DRUG"
        },
        {
          "name": "Tiragolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 204,
      "start_date": "2023-04-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-28",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio • Houston, Texas",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05645692"
    },
    {
      "nct_id": "NCT06424236",
      "title": "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimers Disease",
        "Dementia",
        "Alzheimers Disease, Familial"
      ],
      "interventions": [
        {
          "name": "Gantenerumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 73,
      "start_date": "2020-06-03",
      "completion_date": "2023-11-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06424236"
    },
    {
      "nct_id": "NCT02214121",
      "title": "A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Ticagrelor Dose 1a + Dose 2a",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor Dose 1b + Dose 2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 46,
      "start_date": "2014-09-11",
      "completion_date": "2017-02-27",
      "has_results": true,
      "last_update_posted_date": "2018-12-14",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 6,
      "location_summary": "Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02214121"
    },
    {
      "nct_id": "NCT02266628",
      "title": "Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "RSV-F Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novavax",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 1599,
      "start_date": "2014-10",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2022-05-27",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 10,
      "location_summary": "Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more",
      "locations": [
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02266628"
    },
    {
      "nct_id": "NCT00796887",
      "title": "Randomized, Controlled Trial of Extended-Release Niacin (Niaspan®) to Augment Subacute Ischemic Stroke Recovery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Extended-Release Niacin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry Ford Health System",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 27,
      "start_date": "2009-04",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796887"
    },
    {
      "nct_id": "NCT00080106",
      "title": "Effectiveness of and Immune Response to HIV Vaccination Followed by Treatment Interruption in HIV Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "MRK Ad5 HIV-1 gag vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaccine placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2004-06",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2021-11-09",
      "last_synced_at": "2026-10-23T22:48:54.770Z",
      "location_count": 27,
      "location_summary": "Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00080106"
    }
  ]
}